Physician profile
Ya Li
NPI 1538869300
$1,540.37
in general payments reported to CMS, 2019-2025
24 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $148 · 2024: $1,248 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.37 |
| Education | $194.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $180.94 | 2024 | Rybrevant, Darzalex, Talvey |
| Incyte Corporation | $153.00 | 2024 | Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $148.20 | 2024 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $102.67 | 2024 | Fruzaqla, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $99.33 | 2024 | Calquence |
| Seagen INC. | $95.00 | 2025 | |
| Sobi, INC | $75.02 | 2024 | |
| Eisai INC. | $66.38 | 2024 | |
| Celgene Corporation | $64.70 | 2024 | |
| Exelixis INC. | $63.44 | 2024-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $62.89 | 2024 | Libtayo |
| Daiichi Sankyo INC. | $52.66 | 2024 | Enhertu |
| Taiho Oncology, INC. | $48.37 | 2024 | |
| Janssen Scientific Affairs, LLC | $47.53 | 2023 | Imbruvica |
| Lilly USA, LLC | $41.88 | 2024 | Jaypirca, Verzenio, Retevmo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $34.24 | 2024 | Besremi |
| Karyopharm Therapeutics INC. | $33.02 | 2023 | Xpovio |
| Astellas Pharma US INC | $30.66 | 2024 | Vyloy, Xtandi |
| Abbvie INC. | $29.62 | 2023 | |
| Rigel Pharmaceuticals, INC. | $29.21 | 2024 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $24.12 | 2024 | |
| Adc Therapeutics America, INC. | $23.13 | 2023 | |
| Pfizer INC. | $19.94 | 2024 | |
| Btg International INC. | $14.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ya Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.